Lataa...
Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
PURPOSE: Napabucasin is a cancer stemness inhibitor that targets a number of oncogenic pathways, including signal transducer and activator of transcription 3 (STAT3). Phase 1/2 studies suggest tolerability and anti-tumor activity in various types of cancer; a Phase 3 study of napabucasin plus standa...
Tallennettuna:
| Julkaisussa: | Cancer Chemother Pharmacol |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Berlin Heidelberg
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7188713/ https://ncbi.nlm.nih.gov/pubmed/32236642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04059-3 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|